Global Diabetes Drugs Revenue Is Approximately 52069.55 M USD In 2018
Warning: date() expects parameter 2 to be long, string given in /www/wwwroot/www.globalinforesearch.com/static/themes/default/info_detail.php on line 32
Diabetes drugs are treatments for diabetes by lowering the sugar lower in the blood. Diabetes is a kind of disease with common symptoms such as frequent urination, increased thirst and weight loss. The most common drugs used are insulin and oral medications.
In the past few years, global market of diabetes drugs developed dramatically, with an average growth rate of 15.80%. In 2018, global revenue of diabetes drugs is approximately 52069.55 M USD; the actual sales are around 7393.13 units.
The most common types of diabetes drugs are insulin; DPP-4; GLP-1; SGLT-2 and others. SGLT-2 is a new type of diabetes drugs developed in 2014. The market proportion of SGLT-2 in 2018 is about 5.54%. Insulin has the most market share among these types with a 37.66% market share rate in 2018.
Diabetesr drug are used either for type 1 diabetes or type 2 diabetes. Based on the data. Type 1 diabetes gain the most proportion of diabetes drugs market, with 52.45% in 2008, and the proportion is in an increasing trend from 2013 to 2018.
North America is the largest sales place, with a sales market share about 50.91% in 2008. Following by Europe, with 17.87% in 2018, and China, with 12.05% in 2018.
Market competition is intense. Sanofi, Merck, Novo Nordisk, Eli Lilly, Boehringer Ingelheim etc. are the leading companies of the diabetes drugs industry, and they hold key researches and patents, with high-end customers; have been formed in the monopoly position in the industry. In China, Tonghua Dongbao, Hua Dong and Ganlee is the companies that have the most proportions in Chines Market.